Skip to main content
. 2018 Dec 12;13(12):e0208603. doi: 10.1371/journal.pone.0208603

Fig 2.

Fig 2

A. Time to conversion of L4 versus L6 as measured by Auramine Rhodamine. Survival analysis of smear conversion by AR staining as outcome between Lineage 4 (Euro-American) and Lineage 6 (MAF2), p = 0.0066. MAF2 = Mycobacterium africanum type 2 L4 = 645; L6 = 259 B. Time to conversion of L4 versus L6 as measured by Fluorescein DiAcetate Survival analysis of smear conversion by FDA staining as outcome between Lineage 4 (Euro-American) and Lineage 6 (MAF2), p<0.0001. MAF2 = Mycobacterium africanum type 2; L4 = 645; L6 = 259 C. Time to conversion by lineage as measured by Auramine Rhodamine Survival analysis of smear conversion by AR staining as outcome between Lineage (L) 1, L2, L3, L4, L5 and L6, p = 0.06. L1 = 42 patients; L2 = 16; L3 = 18; L4 = 645; L5 = 16; L6 = 259; M. bovis = 9 D. Time to conversion by lineage as measured by Fluorescein DiAcetate Survival analysis of smear conversion by FDA staining as outcome between Lineage (L) 1, L2, L3, L4, L5 and L6, p<0.01 L1 = 42 patients; L2 = 16; L3 = 18; L4 = 645; L5 = 16; L6 = 259; M. bovis = 9.